Rationale: Lepromatous leprosy is a skin condition. Erythema nodosum leprosum (ENL) aids in its diagnosis. ENL is a type- 2 immune response, whereas lepra ENL is characterized by a hypersensitivity reaction and an exaggerated immune response through a different pathway.
Patient{\textquoteright}s Concern: A 40-year-old male patient, previously diagnosed with lepromatous leprosy, displayed painful skin lesions on his extremities.
Diagnosis: Type-2 lepra reaction, specifically erythema nodosum leprosum.
Interventions: The patient was initially treated with 100 mg dapsone daily and then with fusidic acid, prednisone, and other MDT agents, after development of dapsone resisitance. After type- 2 lepra reaction was lessened in just two weeks, the regimen was adjusted to prednisolone (up to 2 g daily), thalidomide (300 mg daily), minocycline (1.5 g daily), ofloxacin (1 g twice daily), and pentoxifylline (400 mg three times daily) over a six-month period.
Outcomes: The treatment effectively reduced the type-2 lepra reaction and improved the patient{\textquoteright}s skin lesions and overall health.
Lessons: Healthcare providers should maintain a high level of awareness regarding the symptoms and medical history associated with ENL to facilitate timely diagnosis and appropriate management strategies. It is critical to tailor treatment to each patient{\textquoteright}s symptoms and responses for successful management. Consistent monitoring of inflammatory markers and regular follow-up appointments play vital roles in preventing complications and ensuring positive outcomes for patients with ENL.
}, year = {2024}, journal = {Journal of Acute Disease}, volume = {13}, pages = {161-164}, publisher = {Medknow}, issn = {2221-6189, 2589-5516}, url = {https://journals.lww.com/joad/fulltext/2024/13040/erythema_nodosum_leprosum_in_a_patient_with.6.aspx?context=latestarticles$\#$:~:text=Download-,PDF,-EPUB}, doi = {10.4103/jad.jad_78_24}, language = {ENG}, }